BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Thalidomide readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Thalidomide\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06268093-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Thalidomide: Phase 2 readout est. (NCT06268093)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: The Therapeutic Effect of Thalid
 omide in Syringomyelia\nEstimated primary completion: February 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/thalidomide#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06268093
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03069326-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Thalidomide: Phase 2 readout est. (NCT03069326)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: A Clinical Study to Test the Eff
 ects of Ruxolitinib And Thalidomide Combination for Patients With Myelofib
 rosis\nEstimated primary completion: February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03069326
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07476625-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Thalidomide: Phase na readout est. (NCT07476625)
DESCRIPTION:Thalidomide\, phase na.\nStudy: Efficacy and Safety of Thalidom
 ide for Pediatric PFAPA Syndrome\nEstimated primary completion: 31 March 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/thalidomide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07476625
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187193-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270412
DTEND;VALUE=DATE:20270413
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07187193)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Efficacy and Safety of Low-Dose 
 Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH\
 nEstimated primary completion: 12 April 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07187193
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07673302-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270619
DTEND;VALUE=DATE:20270620
SUMMARY:Thalidomide: Phase na readout est. (NCT07673302)
DESCRIPTION:Thalidomide\, phase na.\nStudy: Safety and Efficacy of Hemoglob
 in F Inducers in Patients With Beta Thalassemia\nEstimated primary complet
 ion: 19 June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/th
 alidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07673302
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00572169-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Thalidomide: Phase 3 readout est. (NCT00572169)
DESCRIPTION:Thalidomide\, phase 3\, Multiple Myeloma.\nStudy: UARK 2006-66\
 , Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy\nEstimated 
 primary completion: August 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/thalidomide#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT00572169
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07204041-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07204041)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Efficacy and Safety of XTD Regim
 en (Selinexor\, Thalidomide and Dexamethasone) in Adult Patients With Rela
 psed/Refractory LCH\nEstimated primary completion: 1 August 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/thalidomide#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07204041
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00869232-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT00869232)
DESCRIPTION:Thalidomide\, phase 2\, Multiple Myeloma.\nStudy: UARK 2008-02 
 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Compl
 ete Remission\nEstimated primary completion: October 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT00869232
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03004287-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT03004287)
DESCRIPTION:Thalidomide\, phase 2\, Multiple Myeloma.\nStudy: 2015-12: A St
 udy Exploring the Use of Early and Late Consolidation/Maintenance Therapy\
 nEstimated primary completion: October 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT03004287
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT00871013-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT00871013)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Trial for Patients Not Qualifyin
 g for TT4 and TT5 Protocols Because of Prior Therapy\nEstimated primary co
 mpletion: December 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/thalidomide#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT00871013
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07195799-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07195799)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Linperlisib Combination With Cyc
 lophosphamide\, Prednisone\, and Thalidomide (CPT) in R/R NHL\nEstimated p
 rimary completion: 31 December 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07195799
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07338344-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07338344)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Evaluating the Clinical Efficacy
  and Safety of Luspatercept Combined With Thalidomide in the Treatment of 
 β-TDT Patients\nEstimated primary completion: 31 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/thalidomide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07338344
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933653-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Thalidomide: Phase na readout est. (NCT07933653)
DESCRIPTION:Thalidomide\, phase na.\nStudy: Thalidomide for Preventing Radi
 ation-Induced Dermatitis in Breast Cancer Patients\nEstimated primary comp
 letion: 30 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /thalidomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07933653
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07746245-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07746245)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: The Efficacy of CAPCT in Patient
 s With PTCL\nEstimated primary completion: 31 July 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07746245
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06617182-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20281001
DTEND;VALUE=DATE:20281002
SUMMARY:Thalidomide: Phase 2 readout est. (NCT06617182)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Efficacy and Safety of Thalidomi
 de Combined With Glutamine in the Treatment of Radiation Intestinal Injury
 .\nEstimated primary completion: 1 October 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT06617182
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07671534-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20290630
DTEND;VALUE=DATE:20290701
SUMMARY:Thalidomide: Phase 2 readout est. (NCT07671534)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Metronomic Gemcitabine\, Mitomyc
 in C\, and Thalidomide for Advanced Solid Tumors\nEstimated primary comple
 tion: June 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/thal
 idomide#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07671534
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01356290-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Thalidomide: Phase 2 readout est. (NCT01356290)
DESCRIPTION:Thalidomide\, phase 2.\nStudy: Antiangiogenic Therapy for Child
 ren With Recurrent Medulloblastoma\, Ependymoma\, ATRT and Rare CNS Tumors
 \nEstimated primary completion: April 2030. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/thalidomide#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT01356290
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309419-3130@assetmemo.bio
DTSTAMP:20261121T004456Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Thalidomide: Phase 2/3 readout est. (NCT07309419)
DESCRIPTION:Thalidomide\, phase 2/3.\nStudy: A Phase III Randomized Study o
 f TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targ
 eted Immunotherapy in Unresectable Hepatocellular Carcinoma\nEstimated pri
 mary completion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/thalidomide#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07309419
URL:https://assetmemo.bio/drug/thalidomide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
